Literature DB >> 28364548

Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

Maciej Jurynczyk1, Ruth Geraldes1, Fay Probert2, Mark R Woodhall1, Patrick Waters1, George Tackley1, Gabriele DeLuca1, Saleel Chandratre1, Maria I Leite1, Angela Vincent1, Jacqueline Palace1.   

Abstract

Brain imaging characteristics of MOG antibody disease are largely unknown and it is unclear whether they differ from those of multiple sclerosis and AQP4 antibody disease. The aim of this study was to identify brain imaging discriminators between those three inflammatory central nervous system diseases in adults and children to support diagnostic decisions, drive antibody testing and generate disease mechanism hypotheses. Clinical brain scans of 83 patients with brain lesions (67 in the training and 16 in the validation cohort, 65 adults and 18 children) with MOG antibody (n = 26), AQP4 antibody disease (n = 26) and multiple sclerosis (n = 31) recruited from Oxford neuromyelitis optica and multiple sclerosis clinical services were retrospectively and anonymously scored on a set of 29 predefined magnetic resonance imaging features by two independent raters. Principal component analysis was used to perform an overview of patients without a priori knowledge of the diagnosis. Orthogonal partial least squares discriminant analysis was used to build models separating diagnostic groups and identify best classifiers, which were then tested on an independent cohort set. Adults and children with MOG antibody disease frequently had fluffy brainstem lesions, often located in pons and/or adjacent to fourth ventricle. Children across all conditions showed more frequent bilateral, large, brainstem and deep grey matter lesions. MOG antibody disease spontaneously separated from multiple sclerosis but overlapped with AQP4 antibody disease. Multiple sclerosis was discriminated from MOG antibody disease and from AQP4 antibody disease with high predictive values, while MOG antibody disease could not be accurately discriminated from AQP4 antibody disease. Best classifiers between MOG antibody disease and multiple sclerosis were similar in adults and children, and included ovoid lesions adjacent to the body of lateral ventricles, Dawson's fingers, T1 hypointense lesions (multiple sclerosis), fluffy lesions and three lesions or less (MOG antibody). In the validation cohort patients with antibody-mediated conditions were differentiated from multiple sclerosis with high accuracy. Both antibody-mediated conditions can be clearly separated from multiple sclerosis on conventional brain imaging, both in adults and children. The overlap between MOG antibody oligodendrocytopathy and AQP4 antibody astrocytopathy suggests that the primary immune target is not the main substrate for brain lesion characteristics. This is also supported by the clear distinction between multiple sclerosis and MOG antibody disease both considered primary demyelinating conditions. We identify discriminatory features, which may be useful in classifying atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and relapsing acute disseminated encephalomyelitis, and characterizing cohorts for antibody discovery.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  autoantibodies; magnetic resonance imaging; multiple sclerosis; neuromyelitis optica

Mesh:

Substances:

Year:  2017        PMID: 28364548     DOI: 10.1093/brain/aww350

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  59 in total

1.  Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

Authors:  Divyanshu Dubey; Sean J Pittock; Karl N Krecke; Padraig P Morris; Elia Sechi; Nicholas L Zalewski; Brian G Weinshenker; Eslam Shosha; Claudia F Lucchinetti; James P Fryer; A Sebastian Lopez-Chiriboga; John C Chen; Jiraporn Jitprapaikulsan; Andrew McKeon; Avi Gadoth; B Mark Keegan; Jan-Mendelt Tillema; Elie Naddaf; Marc C Patterson; Kevin Messacar; Kenneth L Tyler; Eoin P Flanagan
Journal:  JAMA Neurol       Date:  2019-03-01       Impact factor: 18.302

Review 2.  [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Authors:  S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

Review 3.  Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.

Authors:  Deena A Tajfirouz; M Tariq Bhatti; John J Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

4.  MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein.

Authors:  Matthias Baumann; Astrid Grams; Tanja Djurdjevic; Eva-Maria Wendel; Christian Lechner; Bettina Behring; Astrid Blaschek; Katharina Diepold; Astrid Eisenkölbl; Joel Fluss; Michael Karenfort; Johannes Koch; Bahadir Konuşkan; Steffen Leiz; Andreas Merkenschlager; Daniela Pohl; Mareike Schimmel; Charlotte Thiels; Barbara Kornek; Kathrin Schanda; Markus Reindl; Kevin Rostásy
Journal:  J Neurol       Date:  2018-02-08       Impact factor: 4.849

Review 5.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

6.  To start immune therapy or not? An unusual presentation of longitudinally extensive transverse myelitis with pyrexia.

Authors:  E Rounis; M I Leite; P M Pretorius; A Sen
Journal:  J Neurol       Date:  2018-05-03       Impact factor: 4.849

7.  Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.

Authors:  Liqin Yang; Haiqing Li; Wei Xia; Chao Quan; Lei Zhou; Daoying Geng; Yuxin Li
Journal:  Eur Radiol       Date:  2019-11-20       Impact factor: 5.315

8.  MRI differences between MOG antibody disease and AQP4 NMOSD.

Authors:  Sara Salama; Majid Khan; Amirali Shanechi; Michael Levy; Izlem Izbudak
Journal:  Mult Scler       Date:  2020-01-15       Impact factor: 6.312

9.  Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease.

Authors:  Sara Salama; Majid Khan; Michael Levy; Izlem Izbudak
Journal:  Mult Scler Relat Disord       Date:  2019-01-10       Impact factor: 4.339

10.  Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder.

Authors:  Sara Salama; Santiago Pardo; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2019-02-22       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.